Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Stemtech International, Inc. provides dietary supplements. Its products include Natural Stem Cell Solution, SE3, SE2, StemEnhance, StemFlo, ST-5 with MigraStem, StemSport, DermaStem, StemPets, and StemEquine. The company was founded by Christian Drapeau and Ray C. Carter Jr. in 2005 and is headquartered in Pembroke Pines, FL.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Part of Founders Combined Charity Income Common Investment Fund, Fondazione Telethon is an Italian company located in Rome that operates as a healthcare charity.\nThe company says this about itself: Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than �� 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments.

San Raffaele Hospital is one of the top centers of Gruppo San Donato (Italy’s largest hospital group, treating over 4.7 million patients yearly). San Raffaele University & Research Hospital is an institute that incorporates clinical, research and university activities altogether, while being internationally recognized for its specialization in some of the most complex pathologies. The hospital is a multi-specialty center with more than 50 clinical specialties covered and over 1300 beds, which is accredited by the Italian National Health System to provide treatment to both public and private, national and international patients. In 2016, the San Raffaele Hospital performed nearly 51,000 patient admissions, 67,700 emergency room interventions and delivered over 7 million healthcare services, including outpatient appointments and diagnostic exams. It is considered to be the most famous hospital in the country and among the most reputable medical centers in Europe.

Hunan Jiaxinbai Biotechnology Co., Ltd., established on 1998-01-07, Business scope includes biotechnology development services;Plant extracts,Class I medical device,Class II medical device,food,solid drink,R&D of cosmetics;Chinese herbal extract,Plant extracts,Class I medical device,Class II medical device,special dietary food,Health food production;nutritious food,drinks,Special Labor Protection Articles,Ordinary Labor Protection Articles,candy,chocolate making;Primary processing of agricultural products;Acquisition of agricultural and sideline products;Agricultural product acquisition;organizational acquisition,Products produced by sales members and similar producers and operators,agricultural products,feed;agricultural products,Pre-packaged food,drinks,Class I medical device,Class II medical device,Cosmetics and hygiene products,Sales of labor protection products;pastry,candy and sugar,Wholesale of sanitation and disinfection products;the tea,Retailing of household appliances and electronics;medicine,Internet transaction service for medical devices;Chain enterprise management;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

JMS Co., Ltd. engages in the manufacture, sale, export, and import of medical devices and pharmaceuticals. Its products include infusion and transfusion sets, disposable needles, syringes, safety scalp vein sets, extension tubes, infusion pumps. blood bags, examination gloves, plastic gloves, treatment sheets, surgical gowns, drainage bags, surgical tapes, central dialysate delivery systems, hemodialysis machines, prefilled syringes, hemodialysis kits, single patient dialysis machines, automatic peritoneal dialysis machines, cardiopulmonary equipment, membrane oxygenator, heat exchangers, pacemakers, micro catheters, and cardiopulmonary blood tubing sets. The company was founded by Taro Tsuchiya in 1952 and is headquartered in Hiroshima, Japan.

ADIENNE provides drug medicine services. Their services include focusing on orphan drug development for the treatment of hematological and immunological diseases, drug design and repositioning, virtual screening, combinatorial chemistry, molecular dynamics, and enzyme design.

Tianjin Darentang No. 2 Pharmaceutical Factory Co. Ltd., a subsidiary of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd., is a company headquartered in Tianjin, China. The firm engages in Chinese traditional medicines production.

Shijiazhuang Ping An Hospital Co., Ltd., established on 2006-11-09, Business scope includes medical services(The operating permit);car park service;Realtor;food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Yizhong Biotechnology Co., Ltd., established on 2000-10-13, Business scope includes research on biomedical products and technologies,to develop,"Four skills"Serve.

Shenzhen Yanxitang Pharmaceutical Technology Co., Ltd., established on 2015-09-08, Business scope includes general business items:Research and development of traditional Chinese medicine technology,consult;Transfer of self-developed technological achievements;Investment in medical research projects;Calligraphy and painting,cultural art design;Cultural exchange event planning;Exhibition planning;Domestic Trade,Engaged in the import and export of goods and technology(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).(Business operations involving pre-administrative licensing,Can operate only after obtaining pre-administrative licensing documents),The licensing program is:

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.